Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections

Abstract

Aim. Comparative study of clinical efficacy and safety of antiviral drug triazavirin and umifenovir in the treatment of patients with acute respiratory viral infections and influenza.
 Methods. The study included 100 patients aged 18 to 65 years diagnosed with moderate acute respiratory viral infection. Group 1 included 34 patients receiving umifenovir 200 mg 4 times a day for 5 days, and comparison group included 32 patients who received triazavirin 1 capsule (250 mg) 3 times a day for 5 days. Group 3 (control group) included 34 patients not treated with antiviral therapy. Efficacy and safety of the studied antiviral drugs were evaluated based on clinical symptoms in the disease course and were confirmed by adaptive reactions of the organism.
 Results. Among patients receiving triazavirin, recovery time and fever, headache and catarrhal syndrome resolution time were less than among patients who received umifenovir. On triazavirin treatment with favorable tolerability, symptomatic medications (antipyretics) were discontinued, and the duration of their use was less, than in patients receiving umifenovir. Evaluation of clinical efficacy of umifenovir and triazavirin for the treatment of acute respiratory viral infections and influenza demonstrated that the drugs effectively reverse the main symptoms of the disease (p <0.05), reduce complications incidence (18.1±2.1% vs. 55.9±3.2%, p <0.05) and contribute to the stabilization of adaptive reactions of the organism in contrast to the results of patients not receiving etiotropic therapy (6.9±2.9% vs. 12.8±2.7, p <0.05). During the use of umifenovir by day 4 and during the use of triazavirin by day 3 intoxication and catarrhal syndromes had been reversed, while in case of the absence of antiviral therapy, 55.8% of patients had continuing intoxication and catarrhal symptoms.
 Conclusion. The results of the study allow defining umifenovir and triazavirin as the first line of defense against acute respiratory viral infections with good efficacy and tolerability of the drugs.

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

“…medication Triazavirin (2-methylsulfanyl-6-nitro [1,2,4]triazolo [5,1-c] [1,2,4]triazin-7-one sodium salt dihydrate) showed a broad spectrum of antiviral action and high efficacy. The medication protects against infection caused by influenza viruses, [6][7][8][9] ARVI, 10 tick-borne encephalitis. 11,12 Triazavirin has been shown to be effective in treating patients with moderate COVID-19.…”

New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways

“…By functioning as molecular glue, Arbidol stabilizes the prefusion conformation of HA that inhibits the large conformational rearrangements associated with membrane fusion in the low pH of the endosome [239]. Arbidol has been found to reverse the main symptoms, reduce incidence of complications and contribute to the stabilisation of adaptive reactions in patients with acute respiratory viral infections [240]. A study of 100 patients with COPD or asthma found that seasonal and post-exposure prophylaxis using Arbidol (Umifenovir) was associated with 2.6-times reduction in influenza and acute respiratory viral infection related morbidity during an epidemic period.…”

Triazavirin—A Novel Effective Antiviral Drug

“…This substance is effective against a wide range of influenza viruses, including H1N1, H3N2, H5N1, H5N2 and H9N2 strains [ 3 , 4 , 5 , 6 , 7 ]. It is worth noting that TZV is a drug with rather low toxicity.…”